reagents for clinical laboratories
Ryvex is pleased to offer you the most innovative solution to your clinical diagnostics platform. The Diazyme line of products uses its proproprietary enzyme technologies to develop diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme’s products include test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes.
Diazyme’s focus is to utilize three platform technologies to develop highly sensitive liquid stable reagents for use on general clinical chemistry analyzers.
The 3 platform technologies include:
1. Enzyme/enzyme cycling technology for assays in the range of µmole/L sensitivity;
2. Latex enhanced immunoassay technology for assays in the range of nmole/L sensitivity;
3. Diazyme’s FemtoQuant™ technology for assays in the range of pmole/L sensitivity. The establishment of the FemtoQuant™ technology allows Diayzme to convert numerous current heterogeneous immunoassays into homogenous enzymatic assays. These homogenous enzymatic assays are run on general clinical chemistry analyzers that are used in clinical laboratories.
Diazyme also carries a chemiluminescent immunoassay technology that has sensitivity close to single molecule detection.
This Single Molecular Sensitive Chemiluminescent Immunoassay (SMS-CLA) technology utilizes alkaline phosphatase labeled antibody tracers to generate specific molecules serving as substrates for Diazyme’s FemtoQuant™ technology that rapidly amplifies chemiluminescent signal for detection.
The SMS-CLA technology allows development of assays that require extreme high sensitivity, such as some tumor markers and cardiac markers, and potentially rapid molecular diagnostics (DNA and RNA tests) without the polymerase chain reaction (PCR) step.
CONTACT US TO FIND OUT IF DIAZYME PRODUCTS CAN BE USED ON YOUR ANALYZERS.